L-Theanine and Caffeine in Combination Affect
Human Cognition as Evidenced by Oscillatory alpha-
Band Activity and Attention Task Performance1–3
1. Simon P. Kelly,
2. Manuel Gomez-Ramirez,
3. Jennifer L. Montesi, and
4. John J. Foxe*
+Author Affiliations
1. Cognitive Neurophysiology Laboratory, Nathan S. Kline Institute for Psychiatric Research,
Program in Cognitive Neuroscience and Schizophrenia, Orangeburg, NY 10962 and Program
in Cognitive Neuroscience, Department of Psychology, City College of the City University of
New York, New York, NY 10031
1. ↵*To whom correspondence should be addressed. E-mail: [email protected].
Next Section
Abstract
Recent neuropharmacological research has suggested that certain constituents of tea may have modulatory
effects on brain state. The bulk of this research has focused on either L-theanine or caffeine ingested alone
(mostly the latter) and has been limited to behavioral testing, subjective rating, or neurophysiological
assessments during resting. Here, we investigated the effects of both L-theanine and caffeine, ingested
separately or together, on behavioral and electrophysiological indices of tonic (background) and phasic (event-
related) visuospatial attentional deployment. Subjects underwent 4 d of testing, ingesting either placebo, 100
mg of L-theanine, 50 mg of caffeine, or these treatments combined. The task involved cued shifts of attention to
the left or right visual hemifield in anticipation of an imperative stimulus requiring discrimination. In addition to
behavioral measures, we examined overall, tonic attentional focus as well as phasic, cue-dependent
anticipatory attentional biasing, as indexed by scalp-recorded alpha-band (8–14 Hz) activity. We found an
increase in hit rate and target discriminability (d′) for the combined treatment relative to placebo, and an
increase in d′ but not hit rate for caffeine alone, whereas no effects were detected for L-theanine alone.
Electrophysiological results did not show increased differential biasing in phasic alpha across hemifields but
showed lower overall tonic alpha power in the combined treatment, similar to previous findings at a larger
dosage of L-theanine alone. This may signify a more generalized tonic deployment of attentional resources to
the visual modality and may underlie the facilitated behavioral performance on the combined ingestion of these
2 major constituents of tea.
Previous SectionNext Section
Introduction
In recent years, several potential health benefits of drinking tea (Camellia sinensis) have come to light through
systematic study of the effects of its constituent compounds (1,2). Although anecdotal evidence abounds, the
psychological and neurophysiological effects of tea have received relatively little experimental investigation and
thus remain unclear. Popular claims have centered on generalized state changes such as the reduction of
stress and induction of relaxed wakefulness. Psychopharmacological studies have indeed demonstrated mood
effects that support these claims and have further shown that tea affects elements of cognition (3,4). Although
caffeine (1,3,7-trimethylxanthine) is by far the constituent most studied, with findings of increased alertness and
speeded reaction time (RT)4 predominant (5,6), there exists evidence that caffeine alone cannot fully account
for the positive effects of tea drinking. Tea has been shown to raise skin temperature to a higher level (7), to
increase critical flicker fusion threshold (4), and to reduce physiological stress responses and increase
relaxation ratings (8) when compared with coffee or other control beverages matched for caffeine level.
L-Theanine (γ-glutamylethylamide), a unique amino acid present almost exclusively in the tea plant, has
recently received research interest in the neuroscience community with findings of neuroprotective effects [see
Kakuda (9)] and mood effects indexed both by subjective self-reports (10) and via psychological and
physiological responses to stress (11). Using electroencephalographic (EEG) recordings in humans, Kobayashi
et al. (12) and Juneja et al. (13) reported that activity within the alpha frequency band (8–14 Hz) increased in
reaction to L-theanine ingestion when measured during a state of rest. This was of interest to the attention
community, as the alpha rhythm has long been known to be sensitive to overall attentional states (i.e., intensity
aspects such as arousal) (14) and, further, is involved in the biasing of selective attention (15,16). In
intersensory attention tasks, where the relevant modality is cued ∼1 s before a compound audiovisual target
stimulus, parieto-occipital alpha power in the intervening period is increased for attend-visual trials relative to
attend-auditory trials (15,17). In Gomez-Ramirez et al. (18), this differential effect of cue information on
anticipatory alpha amplitude was found to be larger on ingestion of 250 mg of L-theanine relative to placebo. In
addition, tonic (background) alpha amplitude was relatively decreased for L-theanine, in apparent contradiction
to the findings of Juneja et al. (13). In a follow-up study, we tested whether an analogous alpha-mediated
attention effect seen in visuospatial attention tasks (16,19–22) is also affected by L-theanine ingestion (M.
Gomez-Ramirez, S. P. Kelly, J. L. Montesi, and J. J. Foxe, unpublished results). L-Theanine, at a dosage of
250 mg, was not found to increase the differential effect of attention. However, in a replication of the previous
intersensory attention study (18), overall tonic alpha was greatly reduced on L-theanine.
An immediate question, given this replication, is whether this tonic alpha reduction occurs at lower dosages
of L-theanine, closer to the amount ingested through a typical serving of tea. In the present study, we
administered a lower dosage of 100 mg to address this. Also of critical interest is whether the ingestion of
caffeine, another major component of tea, exerts behavioral and/or neurophysiological effects during such a
demanding visuospatial attention task, when ingested alone or when ingested together with L-theanine. Here
we present data from a 4-d experiment using a balanced repeated-measures design, with subjects receiving
either placebo (P), L-theanine alone (T), caffeine alone (C), or the combination of L-theanine plus caffeine
(T+C) on each day. We assessed effects of treatment with regard to basic behavioral measures of RT and
accuracy [including the so-called discriminability index (d′), which is independent of individual detection criteria],
and in relation to both tonic and phasic attentional processes as indexed by alpha power.
Previous SectionNext Section
Methods
Participants.
Sixteen (5 female) neurologically normal paid volunteers, aged between 21 and 40 y (mean 27.5 y),
participated in the study. All subjects provided written informed consent, and the Institutional Review Board of
the Nathan S. Kline Institute for Psychiatric Research approved the experimental procedures. All subjects
reported normal or corrected-to-normal vision. Four subjects were left-handed. The mean habitual tea
consumption across the subjects was 3.7 cups/wk, and for coffee, 3.8 cups/wk (∼250 mL/cup). Subjects arrived
at the laboratory in the morning between 0900 and 1200 h, having abstained from all caffeinated beverages for
the previous 24 h.
Treatment.
The timing of treatment administration relative to testing was based on published reports of amino acid
concentration and plasma concentration changes over time.L-Theanine concentration has been found to
increase significantly within 1 h after administration in rats, to continue to increase gradually up to 5 h, and to
decrease thereafter, with complete disappearance evident after 24 h (23). Peak plasma caffeine concentration
is reached between 15 and 120 min postingestion in humans, with a variable half-life typically between 2.5 and
4.5 h (5). Accordingly, participants abstained from consuming caffeine for at least 24 h before testing and
began experimental task runs 30 min after ingestion of any given treatment. Subjects underwent 4 d of testing,
ingesting either placebo, 100 mg of L-theanine, 50 mg of caffeine, or these treatments combined. Subjects
were uninformed of the treatment, which was served in 100 mL of water, with the placebo treatment consisting
only of water. Both theanine and caffeine are tasteless in water solution.
Stimuli and task.
Subjects were seated 150 cm from a CRT monitor and were instructed to maintain fixation on a central cross
(white on midgray background) at all times. Each trial began with a centrally presented arrow cue (“S1”) of 100-
ms duration, with equal probability pointing leftward or rightward toward 1 of 2 bilateral locations centered at a
horizontal distance of 4.2° from the fixation cross and 1.2° above the horizontal meridian. Each location was
marked by 4 dots outlining a 2.4° × 2.4° square. The cue consisted of a circle of 1° diameter with an embedded
arrow, designed to minimize any sensory effects related to physical differences between the left and right cues.
The colors of the arrow and circle were red on green for half of the blocks of recording and green on red for the
other half, with the order counterbalanced across subjects and days of testing. Red and green values were
precalibrated for each subject to be approximately isoluminant by flicker photometry. Then, 933 ms after cue
onset, a second imperative stimulus (“S2”) was presented at the left or right marked location (valid or invalid
with respect to cue direction) with equal probability. The S2s (100 ms duration) consisted of either a white × or
+ (0.75° × 0.75°) embedded in a circular array of 8 small circles such that the overall stimulus diameter was
1.95°. The target stimulus was chosen randomly at the beginning of each experimental run of ∼4.5 min, and
thereafter standard and target stimuli were equally likely on each trial. Subjects were instructed to shift their
attention covertly to the location indicated by the cue, to respond by pressing a mouse button with the index
finger of the right hand when a target S2 appeared on that side, and to ignore stimuli appearing on the invalid
side entirely. Trials were separated by a 1633-ms interval. A total of 100 trials were presented per run. Subjects
completed 20 runs on each day of testing.
Data acquisition.
Continuous EEG data, digitized at 512 Hz, were acquired from 164 scalp electrodes and 4 electro-oculographic
(EOG) electrodes with a pass-band of 0.05–100 Hz. Off-line, the data were low-pass filtered up to 45 Hz and
rereferenced to the nasion. Noisy channels, identified by taking the SD of amplitude over the entire run (from
first to last stimulus presented) and checking whether it is >50% greater than that of at least 3 of the 6 closest
surrounding channels, were interpolated. Horizontal EOG data were recorded using 2 electrodes placed at the
outer canthi of the eyes, allowing measurement of eye movements during testing. Based on a calibrated
mapping of EOG amplitude to visual angle, trials were rejected off-line if eye gaze deviated by >0.5° during the
cue-target interval.
Behavioral data analysis.
We employed a d′ as our principal performance metric, taking into account the accuracy of responding on
nontargets as well as targets and controlling for individual differences in detection criteria. The value of d′ was
derived from the hit rate (proportion of all valid targets detected) and false alarm rate (proportion of all valid
nontargets incorrectly responded to), calculated only from trials containing no eye movements or artifacts.
Ceiling effects on hit rate were corrected in the standard way by assuming 0.5 misses, and similarly, a floor
effect of zero false alarms was corrected to 0.5. RT was measured as the time (in milliseconds) from the point
of S2 onset at which the mouse button was correctly pressed in response to valid target trials.
To control for the potential confound of practice effects on the behavioral data, the order of treatments across
the 4 d of testing was fully counterbalanced across subjects. This is a standard procedure and ensures
unbiased comparison across conditions. However, in the case of the present data, the variance in behavioral
measures arising from the day of testing (order effect) far superseded that arising from treatment. Thus, a
normalization of these measures was necessary to remove the variance caused by practice, and this was
carried out by transforming each data point to a z-score with respect to the mean and SD of all scores
measured on that day (d 1, d 2, d 3, d 4). Because the distribution of scores for each day contains an equal
number of data points from each treatment, it cannot result in any bias for treatment but, rather, optimizes
statistical power to test for treatment effects.
Electrophysiological data analysis.
EEG data were epoched from −300 ms before to 1100 ms after cue onset and baseline-corrected relative to
the interval −100 to 0 ms, with an artifact rejection threshold of ±100 μV applied. Mean alpha amplitude was
calculated using the temporal spectral evolution (TSE) technique (15). TSE is carried out simply by filtering
each epoch with a passband of 8–14 Hz, rectifying, then averaging across trials. The averaged TSE waveforms
were then smoothed by averaging data points within a sliding 100-ms window.
The first analysis concerned tonic (background) alpha amplitude, which was found to decrease on L-theanine in
our previous 2 studies (18, M. Gomez-Ramirez, S. P. Kelly, J. L. Montesi, and J. J. Foxe, unpublished results).
Tonic alpha was measured as the integrated TSE amplitude within the baseline period −200 to 0 before the cue
stimulus, regardless of the direction of attentional deployment (i.e., to the left or right hemifield). The dependent
measure was computed as the baseline alpha amplitude averaged across 6 electrodes, chosen on the basis of
the grand-average scalp distribution of alpha amplitude, collapsed across the 4 d.
In a second analysis, we tested lateralized, anticipatory alpha amplitude for effects of attention and possible
interactions with treatment. We normalized alpha amplitude relative to baseline by dividing the TSE amplitude
by the mean amplitude within the baseline interval (−200 to 0) and log-transforming, making the measure
equivalent to a percentage change from baseline. This narrows down the analysis to attention-related
differential activity, independent of tonic effects. The anticipatory alpha dependent measure was computed as
the integrated TSE amplitude over the postcue interval 500 to 900 ms, ending just before the S2. Amplitude
was averaged across 6 electrodes over each hemisphere, determined based on grand-average difference
topographies (cue-left minus cue-right) collapsed across the 4 d.
Statistical methods.
A 4-d balanced repeated-measures design was employed, with subjects receiving 1 of the 4 treatments
(including placebo) on each day in counterbalanced order. SPSS for Windows (version 12.0) was used for all
statistical analyses. Tests were conducted with an α level of 0.05 unless otherwise stated. In the analysis of
behavioral data, we tested specifically for improvements in performance as a result of any of the 3 treatments.
Thus, 1-tailed, paired t-tests (df = 15) were conducted between the placebo condition and each of the 3
treatments for hit rate, RT, and d′ measures. Because 3 t-tests were performed including the same placebo
data, we applied a Bonferroni-corrected α-level of 0.016 here.
To test for effects of tonic alpha amplitude, a 1-way ANOVA was carried out with the factor of treatment having
the levels P, T, C, and T+C. Follow-up protected ttests were then conducted to unpack significant differences
existing between each of the T, C, and T+C conditions and the P condition. Further post hoc paired
comparisons among the 4 treatment conditions were conducted as appropriate through additional t-tests.
To test for effects on pretarget alpha amplitude a 4 × 2 × 2 ANOVA was carried out with factors of treatment (P,
T, C, T+C), attention (cue-left, cue-right), and hemisphere (left, right). To unpack a potential 3-way interaction,
we reduced the alpha cueing effect (typically seen as a hemisphere × attention interaction) to a single measure
by adding the differential over the 2 hemispheres, i.e., subtracting cue-right from cue-left on the left
hemisphere, subtracting cue-left from cue-right on the right hemisphere, and summing these 2 values. Thus
reduced, testing of treatment effects on the alpha cueing effect, as found in the analogous intersensory study of
Gomez-Ramirez et al. (18), could be done via paired t-tests comparing each of the 3 treatments T, C, and T+C
against P.
Previous SectionNext Section
Results
Behavioral performance.
Behavioral performance was significantly improved on the combined treatment (T+C) in terms of hit rate (P <
0.016) and d′ (P < 0.002). There was also a significant improvement in d′ on C compared with P (P < 0.016),
but not in hit rate. There were no significant effects of L-theanine, and no effects of any of the 3 treatments on
RT (Fig. 1).
Download as PowerPoint Slide
FIGURE 1
Mean hit rate (proportion of targets detected) (upper panel), mean d′ (middle panel), and mean RT (lower
panel) when subjects ingested placebo (P),L-theanine (T), caffeine (C), or these treatments combined (T+C).
Values are means (n = 16). Asterisks indicate difference from P: *P < 0.05, **P < 0.01).
Electrophysiology.
There was a significant effect of treatment on tonic alpha amplitude (P < 0.02). Follow-up t-tests revealed that
alpha was significantly lower for T+C than P (P < 0.02). P did not differ from either T or C (see Fig. 2). Tonic
alpha differed between T+C and T (P < 0.005) but not between T+C and C.
Download as PowerPoint Slide
FIGURE 2
TSE waveforms at midline electrodes from which the baseline tonic alpha measure was derived (upper panel).
Cue-left and cue-right trials are collapsed. Integrated amplitude over the baseline period for each treatment,
with significant difference from placebo marked with an asterisk (lower panel). The electrodes from which tonic
alpha measures were derived are marked on the 168-channel montage.
The typical alpha cueing effect was readily apparent in both the nonnormalized alpha amplitude waveforms and
normalized pretarget measures (Fig. 3) for each treatment day. A strong attention × hemisphere interaction
(P < 0.0005) was found on the pretarget anticipatory alpha measures as expected, reflecting the typically
observed alpha-mediated cueing effect. In addition, there was a significant 3-way interaction among treatment,
attention, and hemisphere (P < 0.05). When we reduced the alpha cueing effect to a single metric as described
above, the effect was smaller on C than P (P < 0.02) but did not differ for the T or T+C conditions.
Download as PowerPoint Slide
FIGURE 3
(Upper panel) TSE waveforms over left and right hemispheres, with cue-left (solid) and cue-right (dashed)
superimposed, collapsed across treatment. The overall alpha-mediated spatial cueing effect is highlighted.
Electrode sites for cueing effect measurement are marked on the montage. (Lower panel) Normalized alpha
measures forming the dependent variable in tests for effects of treatment on the alpha cueing effect (P,
placebo; T, L-theanine; C, caffeine; T+C, combined).
Previous SectionNext Section
Discussion
This study was aimed at extending our knowledge of the effects of compounds contained in tea on the
cognitive function of attention. Testing relatively low-dosage treatments of L-theanine alone (100 mg), caffeine
alone (50 mg), and their combination, we observed an interesting pattern of effects for both behavioral and
electrophysiological measures. Whereas no behavioral effects on hit rate were apparent for either treatment
alone at the low dosages tested here, when both L-theanine and caffeine were ingested together, hit rate
underwent an enhancement of ∼3%. In terms of d′, improvements were seen for both caffeine alone and L-
theanine plus caffeine, the latter having a larger effect size (0.55 vs. 0.42 calculated as Cohen’s d). Given the
absence of any difference in hit rate for caffeine, the d′ effect must result from subjects making fewer false
alarms on caffeine.
Tonic alpha amplitude was not found to decrease significantly on the lower dosage of L-theanine. This indicates
that the effect is dose dependent because a drop was seen in both of our previous studies using a 250-mg
dosage (18, M. Gomez-Ramirez, S. P. Kelly, J. L. Montesi, and J. J. Foxe, unpublished results). There was,
however, a significant decrease in tonic alpha for the combined treatment. That this decrease marks a synergy
between the 2 compounds is suggested by the numerical difference in the alpha decrease caused by L-
theanine with and without caffeine (Fig. 2). That is, it seems unlikely that the greater decrease on the combined
treatment is simply a linear sum of the decreases from each compound alone. Because only single dosages of
each compound were tested, however, a fair degree of caution is appropriate in the interpretation of synergy at
this juncture. This study marks the third finding of decreased alpha as a result of L-theanine ingestion (albeit a
partial cause here) to date, demonstrating the reliability of the effect. At this point, the question of whether it
translates to an improved functional brain state requires serious consideration. Should the finding of a decrease
be received with positive connotations for health and/or mental capabilities?
In the 80 y since the discovery of alpha waves (24), alpha has been measured in almost any experimental
situation and human population, with significant effects abounding, but with a complicated picture and quite
disparate theoretical frameworks arising (25–26). A consistent principle appears to be that stronger alpha infers
positive functioning across individuals (27,28), whereas phasic changes within individuals reflect immediate
stimulus processing and anticipatory enhancement and/or suppression, with a greater retinotopically specific
decrease in alpha being predictive of better detection performance (21). The tonic depression of alpha during
task performance over the day of testing, as observed here, is neither an individual trait nor a phasic event-
related response but a lasting, tonic treatment effect, making it difficult to draw comparisons with such previous
studies. The finding of increased alpha on ingestion of theanine has previously been taken to indicate
increased relaxation without increased drowsiness (13). But this qualification appears tenuous in light of other
observations of treatment-related increased alpha, e.g., during marihuana-induced euphoria (29). Can “good”
and “bad” really be ascribed to increases and decreases in alpha, in whatever direction? Certainly, that this
treatment-related decrease in tonic alpha does not have negative implications is suggested, if not already by
the fact that tea has been keenly, routinely consumed for centuries, by the concomitant facilitation in behavioral
performance found here in terms of both hit rate and d′.
Previous studies have reported a drop in absolute alpha power during resting with eyes open on ingestion of
caffeine at higher dosages, e.g., 200 mg (30) and 400 mg (31). Although alpha amplitude was numerically
lower on 50 mg of caffeine alone here, this did not reach significance (P = 0.18). From this, it is clear that alpha
effects of both L-theanine and caffeine are dose dependent, demonstrating that full characterization of dose-
response functions in future studies is called for.
Evidence of a synergistic relationship between L-theanine and caffeine has been presented in recent
behavioral studies. Parnell et al. (32) reported improved speed and accuracy on an attention-switching task at
60 min and reduced susceptibility to distracting information during a memory task at both 60 and 90 min
following ingestion of a combination of L-theanine and caffeine in the same dosages as used here. Haskell et
al. (33) administered a large battery of cognitive tests before and after consumption of a drink containing either
placebo, 250 mg of L-theanine, 150 mg of caffeine, or their combination. These authors found improvements in
simple and numeric working memory RT, sentence verification accuracy, and alertness ratings for the
combined treatment but not for either treatment alone. Using a similar crossover design but with a greater
dosage of caffeine (250 mg) than L-theanine (200 mg), Rogers et al. (34) found that L-theanine tended to
counteract the caffeine-induced rise in blood pressure but did not interact with caffeine-induced increases in
either alertness or “jitteriness” on state anxiety scales. Although the measures examined in these investigations
and our study are quite distinct in nature, an emerging possibility is that the presence of synergistic effects
closely hinges on dosages. That is, it may be that theanine was not effective in augmenting the caffeine-
induced effects in Rogers et al. (34) because these were present at a saturated level. In the present study,
lower dosages were used, and a significant drop in tonic alpha was observed for L-theanine and caffeine
ingested together but not for either L-theanine or caffeine when ingested alone. However, the absence of a
significant difference between the caffeine-alone and combined treatments calls for caution in making strong
claims of synergy at this point.
Similar to our previous visuospatial attention study (M. Gomez-Ramirez, S. P. Kelly, J. L. Montesi, and J. J.
Foxe, unpublished results), we did not find any change in the alpha differential cueing effect for the L-theanine-
alone treatment. However, it is interesting that the cueing effect was found to be smaller on caffeine alone but
not for the combined treatment. This result was unexpected and thus will bear replication and further
investigation. For now, it appears that within visual space, attentional biasing as indexed by alpha amplitude is
not affected by L-theanine. In contrast, the cued biasing of attention between sensory modalities does appear
to be affected (18). A tentative interpretation of the current pattern of results is thatL-theanine works to enhance
the tonic apportionment of attentional resources to the visual modality and does so to a significant degree when
a large dosage is ingested by itself or in combination with caffeine when a smaller dosage is ingested.
Other articles in this supplement include references (35–44).
Previous SectionNext Section
Footnotes
↵1 Published in a supplement to The Journal of Nutrition. Presented at the conference “Fourth International
Scientific Symposium on Tea and Human Health,” held in Washington, DC at the U.S. Department of
Agriculture on September 18, 2007. The conference was organized by the Tea Council of the U.S.A. and was
cosponsored by the American Cancer Society, the American College of Nutrition, the American Medical
Women’s Association, the American Society for Nutrition, and the Linus Pauling Institute. Its contents are solely
the responsibility of the authors and do not necessarily represent the official views of the Tea Council of the
U.S.A. or the cosponsoring organizations. Supplement coordinators for the supplement publication were
Lenore Arab, University of California, Los Angeles, CA and Jeffrey Blumberg, Tufts University, Boston, MA.
Supplement coordinator disclosure: L. Arab and J. Blumberg received honorarium and travel support from the
Tea Council of the U.S.A. for cochairing the Fourth International Scientific Symposium on Tea and Human
Health and for editorial services provided for this supplement publication; they also serve as members of the
Scientific Advisory Panel of the Tea Council of the U.S.A.
↵2 Author disclosures: S. P. Kelly, M. Gomez-Ramirez, and J. L. Montesi, no conflicts of interest; J. J. Foxe
received an honorarium and travel support from the Tea Council of the U.S.A. for speaking at the Fourth
International Scientific Symposium on Tea and Human Health and for preparing this manuscript for publication.
↵3 Supported by a grant from the Lipton Institute of Tea in association with Unilever Beverages Global
Technology Centre in Colworth House, Sharnbrook, UK.
↵4 Abbreviations used: C, caffeine-alone condition; d′, discriminability index; EEG, electroencephalographic;
EOG, electro-oculographic; P, placebo condition; RT, reaction time; T, theanine-alone condition; T+C,
combined condition; TSE, temporal spectral evolution.
Previous Section
LITERATURE CITED
1. 1.↵
Yang CS, Landau JM. Effects of tea consumption on nutrition and health. J Nutr. 2000;130:2409–12.
Abstract/FREE Full Text
2. 2.↵
Blumberg J. Introduction to the Proceedings of the Third International Scientific Symposium on Tea and
Human Health: role of flavonoids in the diet. J Nutr. 2003;133:3244S–6S.
FREE Full Text
3. 3.↵
Quinlan PT, Lane J, Moore KL, Aspen J, Rycroft JA, O’Brien DC. The acute physiological and mood effects of
tea and coffee: the role of caffeine level.Pharmacol Biochem Behav. 2000;66:19–28.
CrossRefMedline
4. 4.↵
Hindmarch I, Rigney U, Stanley N, Quinlan P, Rycroft J, Lane J. A naturalistic investigation of the effects of
day-long consumption of tea, coffee and water on alertness, sleep onset and sleep
quality. Psychopharmacology (Berl).2000;149:203–16.
CrossRefMedline
5. 5.↵
Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference
to factors that contribute to its widespread use.Pharmacol Rev. 1999;51:83–133.
FREE Full Text
6. 6.↵
Smith A. Effects of caffeine on human behaviour. Food Chem Toxicol.2002;40:1243–55.
CrossRefMedline
7. 7.↵
Quinlan P, Lane J, Aspinall L. Effects of hot tea, coffee and water ingestion on physiological responses and
mood: The role of caffeine, water and beverage type.Psychopharmacology (Berl). 1997;134:164–73.
CrossRefMedline
8. 8.↵
Steptoe A, Gibson EL, Vounonvirta R, Williams ED, Hamer M, Rycroft JA, Erusalimsky JD, Wardle J. The
effects of tea on psychophysiological stress responsivity and post-stress recovery: a randomised double-blind
trial.Psychopharmacology (Berl). 2007;190:81–9.
CrossRefMedline
9. 9.↵
Kakuda T. Neuroprotective effects of the green tea components L-theanine and catechins. Biol Pharm
Bull. 2002;25:1513–8.
CrossRefMedline
10. 10.↵
Lu K, Gray MA, Oliver C, Liley DT, Harrison BJ, Bartholomeusz CF, Phan KL, Nathan PJ. The acute effects
of L-theanine in comparison with alprazolam on anticipatory anxiety in humans. Hum
Psychopharmacol. 2004;19:457–65.
CrossRefMedline
11. 11.↵
Kimura K, Ozeki M, Juneja LR, Ohira H. L-Theanine reduces psychological and physiological stress
responses. Biol Psychol. 2007;74:39–45.
CrossRefMedline
12. 12.↵
Kobayashi K, Nagata Y, Aloi N, Juneja LR, Kim M, Yamamoto T, Sugimoto S. Effects of L-theanine on the
release of α-brain waves in human volunteers. Nihon Nogeikagaku Kaishi. 1998;72:153–7.
13. 13.↵
Juneja LR, Chu DC, Okubo T, Nagato Y, Yokogoshi H. L-Theanine—a unique amino acid of green tea and its
relaxation effect in humans. Trends Food Sci Technol. 1999;10:199–204.
CrossRef
14. 14.↵
Adrian ED, Matthews BHC. The Berger Rhythm: Potential changes in the occipital lobes in
man. Brain. 1934;57:355–85.
FREE Full Text
15. 15.↵
Foxe JJ, Simpson GV, Ahlfors SP. Parieto-occipital ∼10 Hz activity reflects anticipatory state of visual
attention mechanisms. Neuroreport. 1998;9:3929–33.
CrossRefMedline
16. 16.↵
Kelly SP, Lalor EC, Reilly RB, Foxe JJ. Increases in alpha oscillatory power reflect an active retinotopic
mechanism for distracter suppression during sustained visuospatial attention. J
Neurophysiol. 2006;95:3844–51.
Abstract/FREE Full Text
17. 17.↵
Fu KM, Foxe JJ, Murray MM, Higgins BA, Javitt DC, Schroeder CE. Attention-dependent suppression of
distracter visual input can be cross-modally cued as indexed by anticipatory parieto-occipital alpha-band
oscillations. Brain Res Cogn Brain Res. 2001;12:145–52.
CrossRefMedline
18. 18.↵
Gomez-Ramirez M, Higgins BA, Rycroft JA, Owen GN, Mahoney J, Shpaner M, Foxe JJ. The deployment of
intersensory selective attention: a high-density electrical mapping study of the effects of theanine. Clin
Neuropharmacol.2007;30:25–38.
CrossRefMedline
19. 19.↵
Worden MS, Foxe JJ, Wang N, Simpson GV. Anticipatory biasing of visuospatial attention indexed by
retinotopically specific alpha-band EEG increases over occipital cortex. J Neurosci. 2000;20:RC63 (1–6).
20. 20.
Kelly SP, Lalor EC, Reilly RB, Foxe JJ. Visual spatial attention tracking using high-density SSVEP data for
independent brain-computer communication. IEEE Trans Neural Syst Rehabil Eng. 2005;13:172–8.
CrossRefMedline
21. 21.↵
Thut G, Nietzel A, Pascual-Leone A. Alpha-band electroencephalographic activity over occipital cortex
indexes visuospatial attention bias and predicts visual target detection. J Neurosci. 2006;26:9494–502.
Abstract/FREE Full Text
22. 22.↵
Rihs TA, Michel CM, Thut G. Mechanisms of selective inhibition in visual spatial attention are indexed by
alpha-band EEG synchronization. Eur J Neurosci.2007;25:603–10.
CrossRefMedline
23. 23.↵
Terashima T, Takido J, Yokogoshi H. Time-dependent changes of amino acids in the serum, liver, brain and
urine of rats administered with L-theanine.Biosci Biotechnol Biochem. 1999;63:615–8.
CrossRefMedline
24. 24.↵
Berger H. Uber das elecktroenzephalogramm des menschen I. Arch Psychiatr Nervenkr. 1929;87:527–70.
CrossRef
25. 25.↵
Klimesch W, Sauseng P, Hanslmayr S. EEG alpha oscillations: the inhibition-timing hypothesis. Brain Res
Brain Res Rev. 2007;53:63–88.
CrossRefMedline
26. 26.↵
Nunez PL, Wingeier BM, Silberstein RB. Spatial-temporal structures of human alpha rhythms: theory,
microcurrent sources, multiscale measurements, and global binding of local networks. Hum Brain
Mapp. 2001;13:125–64.
CrossRefMedline
27. 27.↵
Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and
analysis. Brain Res Brain Res Rev. 1999;29:169–95.
CrossRefMedline
28. 28.↵
Dockree PM, Kelly SP, Foxe JJ, Reilly RB, Robertson IH. Optimal sustained attention is linked to the spectral
content of background EEG activity: Greater ongoing tonic alpha (∼10 Hz) power supports successful phasic
goal activation.Eur J Neurosci. 2007;25:900–7.
CrossRefMedline
29. 29.↵
Lukas SE, Mendelson JH, Benedikt R. Electroencephalographic correlates of marihuana-induced
euphoria. Drug Alcohol Depend. 1995;37:131–40.
CrossRefMedline
30. 30.↵
Siepmann M, Kirch W. Effects of caffeine on topographic quantitative
EEG.Neuropsychobiology. 2002;45:161–6.
CrossRefMedline
31. 31.↵
Deslandes AC, Veiga H, Cagy M, Piedade R, Pompeu F, Ribeiro P. Effects of caffeine on the
electrophysiological, cognitive and motor responses of the central nervous system. Braz J Med Biol
Res. 2005;38:1077–86.
Medline
32. 32.↵
Parnell H, Owen GN, Rycroft LA. Combined effects of L-theanine and caffeine on cognition and
mood. Appetite. 2006;47:273.
33. 33.↵
Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine, caffeine and their
combination on cognition and mood. Biol Psychol.2008;77:113–22.
CrossRefMedline
34. 34.↵
Rogers PJ, Smith JE, Heatherley SV, Pleydell-Pearce CW. Time for tea: mood, blood pressure and cognitive
performance effects of caffeine and L-theanine administered alone and together. Psychopharmacology
(Berl). 2008;195:569–77.
Medline
35. 35.↵
Arab L, Blumberg JB. Introduction to the Proceedings of the Fourth International Scientific Symposium on Tea
and Human Health. J Nutr.2008;138:1526S–8S.
Medline
36. 36.
Henning SM, Choo JJ, Heber D. Nongallated compared with gallated flavan-3-ols in green and black tea are
more bioavailable. J Nutr. 2008;138:1529S–34S.
Medline
37. 37.
Auger C, Mullen W, Hara Y, Crozier A. Bioavailability of polyphenon E flavan-3-ols in humans with an
ileostomy. J Nutr. 2008;138:1535S–42S.
Medline
38. 38.
Song WO, Chun OK. Tea is the major source of flavan-3-ol and flavonol in the U.S. diet. J
Nutr. 2008;138:1543S–7S.
Medline
39. 39.
Kuriyama S. The relation between green tea consumption and cardiovascular disease as evidenced by
epidemiological studies. J Nutr. 2008;138:1548S–53S.
Medline
40. 40.
Grassi D, Aggio A, Onori L, Croce G, Tiberti S, Ferri C, Ferri L, Desideri G. Tea, flavonoids, and NO-mediated
vascular reactivity. J Nutr. 2008;138:1554S–60S.
Medline
41. 41.
Arts ICW. A review of the epidemiological evidence on tea, flavonoids, and lung cancer. J
Nutr. 2008;138:1561S–6S.
Medline
42. 42.
Hakim IA, Chow HHS, Harris RB. Green tea consumption is associated with decreased DNA damage among
GSTM1 positive smokers regardless of their hOGG1 genotype. J Nutr. 2008;138:1567S–71S.
Medline
43. 43.
Mandel SA, Amit T, Kalfon L, Reznichenko L, Youdim MBH. Targeting multiple neurodegenerative diseases
etiologies with multimodal-acting green tea catechins. J Nutr. 2008;138:1578S–83S.
Medline
44. 44.↵
Stote KS, Baer DJ. Tea consumption may improve biomarkers of insulin sensitivity and risk factors for
diabetes. J Nutr. 2008;138:1584S–8S.
Medline
CiteULike